Biotec Pharmacon's SBG shows promising effect in animal model for inflammatory bowel disease
Researchers at Rikshospitalet University Hospital has presented an abstract from an animal study with SBG for treatment of inflammatory bowel disease on the 3rd World Immune Regulation Meeting in Davos, Switzerland. The study demonstrated that orally administered SBG reduced colitis-associated mortality and bodyweight loss, and also attenuated inflammations and tissue damage in mice that had been induced with experimental ulcerative colitis.
The study is part of Biotec Pharmacon's preclinical efforts with SBG for inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease. Current treatment regimes for IBD are associated with sub-optimal efficacy and significant adverse reactions, and new therapies are thus welcome.
"Our main focus is currently on our more advanced clinical programs for ulcers and wounds and immunotherapy of cancer. However, these findings further support our belief that the effects of SBG on the immune system may open up for medical applications beyond those we already have moved into clinical development," says CEO Lars Viksmoen in Biotec Pharmacon. He adds that Biotec Pharmacon is very excited about the recent findings but that more research needs to be completed before deciding on taking SBG through a clinical development program for IBD.
Other news from the department research and development
